Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Concordia Healthcare Corp. T.CXR.R

TSX:CXR.R - Post Discussion

Concordia Healthcare Corp. > MARKET CHATTER
View:
Post by riddle5 on Oct 14, 2015 11:36am

MARKET CHATTER

Market Chatter: Concordia Healthcare Hits New 52-Week Low - Goldman Sachs Reportedly Struggles to Sell Concordia Debtless than 1 minute ago

11:14 AM EDT, 10/14/2015 (MT Newswires) -- Shares of Concordia Healthcare Corp. (CXRX) touched a new 12-month low Wednesday after Bloomberg reported that Goldman Sachs (GS) and other banks are struggling to sell nearly $2.8 billion of the pharmaceutical company's debt due to the ongoing drug-pricing controversy plaguing the pharmaceutical sector.

According to sources cited by Bloomberg, Goldman Sachs and other unnamed banks that committed to financing Concordia's purchase of drugmaker Amdipharm Mercury are facing low demand for two term loans totaling $1.86 billion. The loans are being marketed to back the takeover, sources noted adding that the banks plan to issue up to $950 million of bonds.

Concordia plans to finalize the acquisition next week, Bloomberg said.

CXRX was marginally higher in recent trade, with a new 52-week range of $30.76 to $73.23.

Price: 33.09, Change: +0.51, Percent Change: +1.57

Comment by poubelle1 on Oct 14, 2015 12:08pm
The company overpaid for this acquisition. They are fools. They should renegotiate the deal with lower debt, or walk away. Probably not possible. But they definitely overpaid.
Comment by healthstock1234 on Oct 14, 2015 12:40pm
The risk of the debt was calculated to be absorbed by new body-after the acquisition.Good reputation, new body and US market.
Comment by healthstock1234 on Oct 14, 2015 12:49pm
big acquisition, debt involved so a little bit risky,less than 7 days,Hillary emails regarding the industry,S&P/TSX, DOW ,NASDAQ sometimes green sometimes red,so, just high volatility?!
Comment by RusticHit on Oct 14, 2015 1:08pm
Look like A Capitulation day today 40 support tested and Bounced nicely ,lets  see where it end up ??
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities